ClinicalTrials.gg

Program

dexamethasone phosphate

Also written as “Moxidex otic solution”, “Dexamethasone sodium phosphate” and “Dexamethasone Phosphate Ophthalmic Solution”.

Its studies are mostly in Otitis Media · Ataxia Telangiectasia · Peripheral Arterial Disease · Uveitis, Anterior · Cataract, led by 5 companies.

Furthest: phase 4, since May 20, 201020 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eyegate Pharmaceuticals70 open or runningphase 3since May 20, 2010Jun 5, 2008none ahead
Alcon60 open or runningphase 3since Dec 19, 2007Dec 19, 2007none ahead
Quince Therapeutics30 open or runningphase 3since Dec 11, 2023Jul 28, 2010none ahead
Mercator MedSystems20 open or runningphase 4since Nov 4, 2013Nov 4, 2013none ahead
Taiwan Liposome20 open or runningphase 2since Nov 13, 2013Nov 13, 2013none ahead

Also a collaborator on its studies: biotrial.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 6 studies since Dec 19, 2007.

  1. Oct 2, 2008Phase 2 study in Dry Eye SyndromesEyegate Pharmaceuticals · NCT00765804 · 89 enrolled · United States
  2. Feb 18, 2010Phase 3 study in Otitis MediaAlcon · NCT01071902 · 400 enrolled · United States
  3. May 20, 2010Phase 3 study in Dry Eye SyndromesEyegate Pharmaceuticals · NCT01129856 · 198 enrolled · United States
  4. Jul 28, 2010Quince Therapeutics's first study: phase 2 study in Colitis, UlcerativeNew to Quince TherapeuticsQuince Therapeutics · NCT01171807 · 33 enrolled · Italy
  5. Nov 4, 2013Mercator MedSystems's first study: phase 4 study in Peripheral Arterial DiseaseNew to Mercator MedSystemsMercator MedSystems · NCT01983449 · 285 enrolled · United States
  6. Nov 13, 2013Taiwan Liposome's first study: phase 2 study in Macular EdemaNew to Taiwan LiposomeTaiwan Liposome · NCT02006147 · 14 enrolled · Taiwan
  7. Aug 5, 2015Phase 3 study in Uveitis, AnteriorEyegate Pharmaceuticals · NCT02517619 · 251 enrolled · United States
  8. Oct 6, 2015Phase 2 study in Patients Having Undergone Unilateral Cataract Extraction and Implantation of a MonofocalEyegate Pharmaceuticals · NCT02571556 · 80 enrolled · United States
  9. Dec 22, 2015Phase 1 study in VitrectomyEyegate Pharmaceuticals · NCT02644694 · 10 enrolled · United States
  10. Mar 22, 2017Phase 2 study in Retinal Vein OcclusionTaiwan Liposome · NCT03093701 · 31 enrolled · United States
  11. Jun 5, 2017Phase 2 study in CataractEyegate Pharmaceuticals · NCT03180255 · 101 enrolled · United States
  12. May 6, 2019Phase 2 study in Peripheral Arterial DiseaseMercator MedSystems · NCT03942601 · 10 enrolled · United States
  13. Dec 11, 2023Phase 3 study in Ataxia TelangiectasiaQuince Therapeutics · NCT06193200 · 105 enrolled · United States, Denmark, Germany and more
  14. Oct 25, 2024Phase 3 study in Ataxia TelangiectasiaQuince Therapeutics · NCT06664853 · 101 enrolled · United States, Denmark, Germany and more

TargetBeta

NR3C1 →read by rule
“Glucocorticoid receptor agonist”ChEMBL 37, by rule

Other programs on NR3C1

ProgramCompanyFurthest phaseStudies
DexamethasoneruleAbbViephase 4174
BudesonideruleAstraZenecaphase 4167
fluticasone furoateruleGlaxoSmithKlinephase 497
PrednisoneruleJohnson & Johnsonphase 465
BeclomethasoneruleChiesi Farmaceuticiphase 446
PrednisoloneruleSanofiphase 434
betamethasone dipropionateruleLEO Pharmaphase 427
MethylprednisolonerulePfizerphase 423
vamorolonerulereveragen-biopharma-incphase 411
BetamethasoneruleLEO Pharmaphase 49
Triamcinoloneruleresearch-insight-llcphase 45
relacorilantruleCorcept Therapeuticsphase 322

Studies

All 20 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06664853Ataxia Telangiectasia · United States, Denmark, Germany and more3TerminatedQuince TherapeuticsJan 30, 2026101
NCT06193200Ataxia Telangiectasia · United States, Denmark, Germany and more3CompletedQuince TherapeuticsDec 17, 2025105
NCT03942601Peripheral Arterial Disease · United States2TerminatedMercator MedSystemsApr 30, 202110
NCT03180255Cataract · United States2CompletedEyegate PharmaceuticalsNov 7, 2017101
NCT03093701Retinal Vein Occlusion · United States2CompletedTaiwan LiposomeFeb 4, 201931
NCT02644694Vitrectomy · United States1CompletedEyegate PharmaceuticalsOct 201610
NCT02571556Patients Having Undergone Unilateral Cataract Extraction and Implantation of a Monofocal · United States2CompletedEyegate PharmaceuticalsOct 201680
NCT02517619Uveitis, Anterior · United States3CompletedEyegate PharmaceuticalsApr 20, 2018251
NCT02006147Macular Edema · Taiwan2CompletedTaiwan LiposomeJul 15, 202014
NCT01983449Peripheral Arterial Disease · United States4CompletedMercator MedSystemsDec 2016285
NCT01171807Colitis, Ulcerative · Italy2CompletedQuince TherapeuticsMay 15, 200733
NCT01129856Dry Eye Syndromes · United States3CompletedEyegate PharmaceuticalsJan 2011198
NCT01071902Otitis Media · United States3TerminatedAlconOct 2011400
NCT00765804Dry Eye Syndromes · United States2CompletedEyegate PharmaceuticalsFeb 200989
NCT00750633Otitis Externa3CompletedAlconJan 2009990
NCT00694135Uveitis, Anterior · United States, India2CompletedEyegate PharmaceuticalsJul 200940
NCT00579189Otitis Media3CompletedAlconJan 2009776
NCT00579020Corneal Diseases · United States2TerminatedAlconFeb 2009144
NCT00578773Otitis Media2CompletedAlconJan 2009303
NCT00578474Otitis Media3CompletedAlconAug 2008911

How it is read

Names in the registry

  • “Moxidex otic solution”, 5 entries
  • “Dexamethasone sodium phosphate”, 2 entries
  • “Dexamethasone Phosphate Ophthalmic Solution”, 2 entries
  • “Low-dose TGF-B3 and Dexamethasone Sodium Phosphate”, 1 entry
  • “High-dose TGF-B3 and Dexamethasone Sodium Phosphate”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.